Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN versus MIDOZALAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN versus MIDOZALAM HYDROCHLORIDE.
KLONOPIN vs MIDOZALAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that binds to GABA-A receptors at the benzodiazepine binding site, enhancing the effect of GABA and increasing chloride ion influx, leading to neuronal hyperpolarization and decreased neuronal excitability.
Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.
0.5 mg orally three times daily; maximum 20 mg/day
2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.
None Documented
None Documented
30-40 hours in adults; prolonged in elderly (up to 50-80 hours) and hepatic impairment; clinical context: steady-state achieved in 5-10 days
Terminal elimination half-life: 1.5-3 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity, hepatic cirrhosis (up to 20 hours), and congestive heart failure.
Renal excretion: ~50-70% as glucuronide metabolites, ~30% as unchanged drug (with enterohepatic recirculation); fecal: <2%
Renal excretion of metabolites (approximately 90% as glucuronide conjugates, with less than 1% unchanged drug) and biliary/fecal excretion (approximately 5-10%).
Category C
Category C
Benzodiazepine
Benzodiazepine